ATAnne M. Talkington

Anne M. Talkington

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anne M. Talkington has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimization of Immune Checkpoint Blockade via a Multiscale Model System

    by Anne M. Talkington, Anthony J. Kearsley

    Cancer progresses when cancer cells selectively bind to inhibitory receptors on a T cell surface, downregulating tumor immune response. One standard‐of‐care strategy to combat this process is immune checkpoint blockade. Immune checkpoint blockade occurs when a therapeutic agent binds to, and inhibits, inhibitory receptors on a T cell surface, such that immune stimulation is favored when T cells and cancer cells interact. However, many cancers fail to respond to immune checkpoint blockade treatments. Here we explore a whole‐tumor and an individual cell‐focused model system to test expected outcomes of blockade perturbations in tumor‐immune interactions. We first observe a transition point at which patients become more likely to reach “remission” or “stable disease” as a terminal state, and a “progressive disease” state is less likely. We propose a physical, agent‐based framework for testing blockade strategies at the cellular level. This offers valuable guidance for blockade efficacy optimization in future development and design of therapeutic antibodies.

  • Open Access

    Uncovering Cellular Interactome Drivers of Immune Checkpoint Inhibitor Response in Advanced Melanoma Patients

    by Shay Ladd, Anne M. Talkington, Mary O’sUllivan, Robert W. Barnes, Remziye E. Wessel, Gabriel F. Hanson, Sepideh Dolatshahi

    Purpose: Despite the success of immune checkpoint inhibitors (ICIs) that target immunosuppressive interactions, treatment resistance remains a major clinical challenge. The tumor microenvironment is comprised of tumor, immune, and stromal cell types that communicate through secreted and cell surface proteins. This can be represented by a weighted, directed network where pairs of cell types communicate via multiple ligand-receptor interactions with varying strengths. Identifying interaction network motifs that are linked with outcome or evolve pre- to post-ICI presents a rational framework to identify combination therapeutic targets. Methods: Interaction inference was performed on publicly available single-cell RNA-sequencing data from melanoma patients. The constructed patient-specific networks were input to multivariate statistical learning approaches to identify network motifs that predicted response pre-treatment and that shifted pre- to post-treatment. Relevance of interactions was validated by (1) differential expression of related pathways in single cell RNA sequencing (scRNA-seq) data, (2) survival associations in an independent bulk RNA-seq dataset, and (3) repeated analyses of scRNA-seq data in a second cohort. Results: Immune-immune interactions with roles in T cell activation, chemotaxis, and adhesion were upregulated in patients who respond to therapy pre-treatment. Related pathways were perturbed in involved immune cells and expression of these genes was associated with improved survival. The interactome also distinguished pre- and post-treatment biopsies with high accuracy despite no significant differences in individual interactions. Analysis in the validation dataset with mixed responses pre-treatment recapitulated results from the discovery analyses. Conclusion: Unbiased analysis of interaction networks and their evolution is a powerful framework to guide prognostic indicators and novel combination targets to improve patient outcomes.


  • Immersive Visualization of a 3D Model of Tumor-Immune Dynamics

    by Anne M. Talkington, Steven G. Satterfield, Anthony J. Kearsley

  • Pegloticase co-administered with high MW polyethylene glycol effectively reduces PEG-immunogenicity and restores prolonged circulation in mouse

    by Zhongbo Li, Limei Shen, Alice Ma, Anne Talkington, Zibo Li, Andrew C. Nyborg, M. Scott Bowers, Brian LaMoreaux, Eric W. Livingston, Jonathan E. Frank, et al.


  • Open Access

    GeoTyper: Automated Pipeline from Raw scRNA-Seq Data to Cell Type Identification

    by Cecily Wolfe, Yayi Feng, David Chen, Edwin Purcell, Anne Talkington, Sepideh Dolatshahi, Heman Shakeri

    The cellular composition of the tumor microenvironment can directly impact cancer progression and the efficacy of therapeutics. Understanding immune cell activity, the body's natural defense mechanism, in the vicinity of cancerous cells is essential for developing beneficial treatments. Single cell RNA sequencing (scRNA-seq) enables the examination of gene expression on an individual cell basis, providing crucial information regarding both the disturbances in cell functioning caused by cancer and cell-cell communication in the tumor microenvironment. This novel technique generates large amounts of data, which require proper processing. Various tools exist to facilitate this processing but need to be organized to standardize the workflow from data wrangling to visualization, cell type identification, and analysis of changes in cellular activity, both from the standpoint of malignant cells and immune stromal cells that eliminate them. We aimed to develop a standardized pipeline (GeoTyper, https://github.com/celineyayifeng/GeoTyper) that integrates multiple scRNA-seq tools for processing raw sequence data extracted from NCBI GEO, visualization of results, statistical analysis, and cell type identification. This pipeline leverages existing tools, such as Cellranger from 10X Genomics, Alevin, and Seurat, to cluster cells and identify cell types based on gene expression profiles. We successfully tested and validated the pipeline on several publicly available scRNA-seq datasets, resulting in clusters corresponding to distinct cell types. By determining the cell types and their respective frequencies in the tumor microenvironment across multiple cancers, this workflow will help quantify changes in gene expression related to cell-cell communication and identify possible therapeutic targets.

  • A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes

    by Anne M. Talkington, Morgan D. McSweeney, Timothy Wessler, Marielle K. Rath, Zibo Li, Tao Zhang, Hong Yuan, Jonathan E. Frank, M. Gregory Forest, Yanguang Cao, et al.


  • Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery

    by Anne M. Talkington, Timothy Wessler, Samuel K. Lai, Yanguang Cao, M. Gregory Forest

    Physiologically-based pharmacokinetic (PBPK) modeling is a popular drug development tool that integrates physiology, drug physicochemical properties, preclinical data, and clinical information to predict drug systemic disposition. Since PBPK models seek to capture complex physiology, parameter uncertainty and variability is a prevailing challenge: there are often more compartments (e.g., organs, each with drug flux and retention mechanisms, and associated model parameters) than can be simultaneously measured. To improve the fidelity of PBPK modeling, one approach is to search and optimize within the high-dimensional model parameter space, based on experimental time-series measurements of drug distributions. Here, we employ Latin Hypercube Sampling (LHS) on a PBPK model of PEG-liposomes (PL) that tracks biodistribution in an 8-compartment mouse circulatory system, in the presence (APA+) or absence (naïve) of anti-PEG antibodies (APA). Near-continuous experimental measurements of PL concentration during the first hour post-injection from the liver, spleen, kidney, muscle, lung, and blood plasma, based on PET/CT imaging in live mice, are used as truth sets with LHS to infer optimal parameter ranges for the full PBPK model. The data and model quantify that PL retention in the liver is the primary differentiator of biodistribution patterns in naïve versus APA+ mice, and spleen the secondary differentiator. Retention of PEGylated nanomedicines is substantially amplified in APA+ mice, likely due to PL-bound APA engaging specific receptors in the liver and spleen that bind antibody Fc domains. Our work illustrates how applying LHS to PBPK models can further mechanistic understanding of the biodistribution and antibody-mediated clearance of specific drugs.


  • A semi-automated finite difference mesh creation method for use with immersed boundary software IB2d and IBAMR

    by D Michael Senter, Dylan R Douglas, W Christopher Strickland, Steven G Thomas, Anne M Talkington, Laura A Miller, Nicholas A Battista

    Numerous fluid-structure interaction problems in biology have been investigated using the immersed boundary method. The advantage of this method is that complex geometries, e.g., internal or external morphology, can easily be handled without the need to generate matching grids for both the fluid and the structure. Consequently, the difficulty of modeling the structure lies often in discretizing the boundary of the complex geometry (morphology). Both commercial and open source mesh generators for finite element methods have long been established; however, the traditional immersed boundary method is based on a finite difference discretization of the structure. Here we present a software library for obtaining finite difference discretizations of boundaries for direct use in the 2D immersed boundary method. This library provides tools for extracting such boundaries as discrete mesh points from digital images. We give several examples of how the method can be applied that include passing flow through the veins of insect wings, within lymphatic capillaries, and around starfish using open-source immersed boundary software.